Your selection
NoneFilter by content type
Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
October 7, 2021 - … With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021 10.07.2021 This release is a backfill from a News Wire … first and only approved KRAS G12C inhibitor, in more than 10 different investigational combination regimens for the … Amgen , including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …
Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
October 7, 2021 - … to Accelerate Novel Precision Therapies for Brain Diseases 10.07.2021 This release is a backfill from a News Wire … by Amgen , including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …
Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment
October 4, 2021 - … Global Trends In Hip Fracture Incidence And Treatment 10.04.2021 This release is a backfill from a News Wire … by Amgen , including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …
Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
October 2, 2021 - … With Moderate-to-Severe Atopic Dermatitis At EADV Congress 10.02.2021 This release is a backfill from a News Wire …
FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
September 24, 2021 - … Approves Repatha(R) (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia … Approves Repatha(R) (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia … Amgen , including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …
Amgen Wins Patent Case on Otezla® (apremilast)
September 20, 2021 - … -- but ruled against Amgen on claims in U.S. Patent No. 10,092,541 covering methods of treating psoriasis with … in U.S. Patent Nos. 7,427,638, 7,893,101, 8,455,536, and 10,092,541, and Zydus acknowledged that its generic version … Amgen , including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …
Amgen Releases 8th Edition of Biosimilar Trends Report
September 22, 2021 - … and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines THOUSAND OAKS, Calif. , Sept. 22, … and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines THOUSAND OAKS, Calif. , Sept. 22, … and Invested Close to $2 Billion Across a Portfolio of 10 Biosimilar Medicines THOUSAND OAKS, Calif. , Sept. 22, …
LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
September 16, 2021 - … pretreated (median of two prior lines of therapy; range 1-10) KRAS G12C-mutated metastatic CRC were enrolled in the … TRAEs were observed. The most common TRAEs (occurring in > 10% of patients) were consistent with known adverse events … Amgen , including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …
9-13-2021 - … Filer AMGEN INC Filing Date 09.13.2021 Document Date 09. 10 .2021 Form Description Statement of changes in beneficial … Filer AMGEN INC Filing Date 09.13.2021 Document Date 09. 10 .2021 Form Description Statement of changes in beneficial … Filer AMGEN INC Filing Date 09.13.2021 Document Date 09. 10 .2021 Form Description Statement of changes in beneficial …
Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
September 13, 2021 - … Session: Late-breaking News , Saturday, Oct. 2 from 10:15-10:30 am CEST Otezla Clinical Data Abstracts Improvement in … Amgen , including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and …